Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK

Journal of the Royal Society of Medicine

Volumn 97, Issue 5, 2004, Pages 226-229

  Greene, Owen ^a   Durrington, Paul ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GROUPS BY AGE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; UNITED KINGDOM; BLOOD; FEASIBILITY STUDY; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE 2; REVIEW;

ADOLESCENT; ADULT; ANTILIPEMIC AGENTS; CHILD; CHOLESTEROL; FEASIBILITY STUDIES; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE;

EID: 2442679496     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.97.5.226     Document Type: Article

References (22)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th edn. New York: McGraw-Hill, 1995:1981-2030
2. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis 2003;168:1-14
3. Durrington PN. Dyslipidaemia. Lancet 2003;362:717-31
4. Leonard JV, Whitelow AG, Wolff OH, Lloyd JK, Slack J. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. BMJ 1977;i:1566-8
5. Simon Broome Register Group (Scientific Steering Committee). Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6
6. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999;142:105-12
7. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980;ii:873-5
8. de Jongh S, Ose L, Szamosi T, et al. Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterokemia. A randomised, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7
9. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1966;97:619-28
10. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in childhood. A study in familial hypercholesterolaemia heterozygotes and their siblings. Lancet 2004;363:369-70
11. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81
12. Slack J. Risk of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969;ii:1380-2
13. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Findings from the PDAY Study. Atheroscler Thromb 1993;13:1291-8
14. Berenson GS, Wattigney WA, Tracey Re, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol 1992;70:851-8
15. De Jongh S, Lilien MR, Op't Roodt J, Stroes ES, Bakker HD, Kastelein JP. Early statin therapy restores endothelial function in children with familial hypercholesterolaemia. J Am Coll Cardiol 2002;40:2117-21
16. Betteridge DJ, Bhatnagar D, Bing D, et al. Treatment of familial hypercholesterolaemia. The United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992;304:1335-8
17. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64
18. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326: 1423-7
19. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of diagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148
20. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ 1985;295:1671-3
21. Christensen B, Glueck C, Kwiterovich P, et al. Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the prevalence study of the Lipid Research Clinics Program. Pediat Res 1980;14:194-202
22. Gagne C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91